Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a southwest oncology group clinical trial

Clinical Cancer Research

Volumn 15, Issue 16, 2009, Pages 5258-5266

  Choi, Ji Yeob ^a,c   Barlow, William E ^d   Albain, Kathy S ^e   Hong, Chi Chen ^a   Blanco, Javier G ^b   Livingston, Robert B ^f   Davis, Warren ^a   Rae, James M ^g   Yeh, I Tien ^h   Hutchins, Laura F ⁱ   Ravdin, Peter M ^h   Martino, Silvana ^j   Lyss, Alan P ^k   Osborne, C Kent ^l   Abeloff, Martin D ^m   Hayes, Daniel F ^g   Ambrosone, Christine B ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Inje University College of Medicine   (South Korea)

^d SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^e LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h Mays Cancer Center at UT Health San Antonio   (United States)

ⁱ UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^j Angeles Clinic and Research Institute   (United States)

^k MISSOURI BAPTIST MEDICAL CENTER   (United States)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; NITRIC OXIDE SYNTHASE; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; GENOTYPE; HIGH RISK POPULATION; HUMAN; LYMPH NODE; MULTIPLE CYCLE TREATMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CISPLATIN; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; MEDICAL ONCOLOGY; METHOTREXATE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC; PROGNOSIS; SOUTHWESTERN UNITED STATES;

EID: 69349095566     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0685     Document Type: Article

References (60)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Abe O, Abe R, Enomoto K, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-2106 (Pubitemid 41797643)
4. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312
5. Strauss G, Westhoff M, Fischer-Posovszky P, et al. 4-Hydroperoxy- cyclophosphamidemediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ 2008;15:332-343
6. Murata M, Suzuki T, Midorikawa K, Oikawa S, Kawanishi S. Oxidative DNA damage induced by a hydroperoxide derivative of cyclophosphamide. Free Radic Biol Med 2004;37:793-802. (Pubitemid 39078551)
7. Tsai-Turton M, Luong BT, Tan Y, Luderer U. Cyclophosphamide- induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci 2007;98: 216-230 (Pubitemid 47073834)
8. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56:185-229. (Pubitemid 38720829)
9. Choi J, Nowell SA, Blanco JG, Ambrosone CB. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 2006;7:613-624 (Pubitemid 43891417)
10. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012
11. Ahsan A, Norboo T, Baig MA, Pasha MAQ. Simultaneous selection of the wild-type genotypes of the G894T and 4B/4A polymorphisms of NOS3 associate with high-altitude adaptation. Ann Hum Genet 2005;69:260-267 (Pubitemid 40613727)
12. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci U S A 2000;97:2832-2835 (Pubitemid 30159257)
13. Nakayama M, Yasue H, Yoshimura M, et al. T-786→C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99:2864-2870 (Pubitemid 29258973)
14. Celli CM, Tran N, Knox R, Jaiswal AK. NRH: quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol 2006;72:366-376 (Pubitemid 43975085)
15. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997;75:69-75. (Pubitemid 27007275)
16. Ross D, Traver RD, Siegel D, Kuehl BL, Misra V, Rauth AM. A polymorphism in NAD(P)H:Quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 1996;74:995-996 (Pubitemid 26319344)
17. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 2001;59:263-268 (Pubitemid 32108559)
18. Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, Cairo G. Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol 2004;340-361 (Pubitemid 38248585)
19. Hoffmann F, Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev2007;39:87-144.
20. Lopez de Cerain A, Marin A, Idoate MA, Tunon MT, Bello J. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur J Cancer 1999;35:320-324 (Pubitemid 29136786)
21. Covarrubias VG, Lakhman SS, Forrest A, Relling MV, Blanco JG. Higher activity of polymorphic NAD(P)H:Quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol Lett 2006;164:249-258 (Pubitemid 43766794)
22. Lakhman SS, Ghosh D, Blanco JG. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos 2005;33:254-257 (Pubitemid 40220348)
23. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-1184 (Pubitemid 41258223)
24. Hutchins LF, Green SJ, Ravdin PM, et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of intergroup protocol INT-0102. J Clin Oncol 2005;23:8313-8321
25. Bonadonna G, Brusamolino E, Valagussa P. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-410
26. Bull JM, Tormey DC, Li SH. A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy. Cancer 1978;41:1649-1657 (Pubitemid 8335369)
27. Ambrosone CB, Barlow WE, Reynolds W, et al. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early stage breast cancer in SWOG 8897. J Clin Oncol. In press 2009.
28. Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD. Genotyping for polymorphic drug metabolizing enzymes from paraffin- embedded and immunohistochemically stained tumor samples. Pharmacogenetics 2003;13:501-507
29. Jenkins DC, Charles IG, Thomsen LL, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A 1995;92:4392-4396
30. Lancaster JR, Jr., Xie K. Tumors face NO problems? Cancer Res 2006;66:6459-6462
31. Rigas B. Novel agents for cancer prevention based on nitric oxide. Biochem Soc Trans 2007; 35:1364-1368 (Pubitemid 350206501)
32. Lala PK, Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev1998;17:91-106.
33. Jadeski LC, Chakraborty C, Lala PK. Nitric oxide- mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen- activated protein kinase. Int J Cancer 2003;106:496-504. (Pubitemid 36966204)
34. Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature 2008;452:646-649
35. Shang ZJ, Li JR. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression. J Oral Pathol Med 2005;34:134-139 (Pubitemid 40293221)
36. Felley-Bosco E. Role of nitric oxide in genotoxicity: implication for carcinogenesis. Cancer Metastasis Rev1998;17:25-37.
37. Ambs S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 1997;11:443-448 (Pubitemid 27259985)
38. Choi JY, Lee KM, Noh DY, et al. Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 2006;100:213-218 (Pubitemid 44631923)
39. Mortensen K, Holck S, Christensen IJ, et al. Endothelial cell nitric oxide synthase in peritumoral microvessels is a favorable prognostic indicator in premenopausal breast cancer patients. Clin Cancer Res 1999;5:1093-1097 (Pubitemid 29233224)
40. Martin JH, Begum S, Alalami O, Harrison A, Scott KW. Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer. Tumour Biol 2000;21:90-97 (Pubitemid 30114654)
41. Frederiksen LJ, Sullivan R, Maxwell LR, et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 2007; 13:2199-2206
42. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 2001;93:1879-1885 (Pubitemid 34048655)
43. Muir CP, Adams MA, Graham CH. Nitric oxide attenuates resistance to doxorubicin in threedimensional aggregates of human breast carcinoma cells. Breast Cancer Res Treat 2006;96:169-176
44. Huerta S, Chilka S, Bonavida B. Nitric oxide donors: novel cancer therapeutics [review]. Int J Oncol 2008;33:909-927
45. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase- akt pathway in human endothelial cells. Circ Res 2000;87:677-682 (Pubitemid 30778315)
46. Haynes MP, Li L, Sinha D, et al. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 2003;278: 2118-2123 (Pubitemid 36801275)
47. Loibl S, Bratengeier J, Farines V, et al. Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7-estrogen has an influence on e-NOS, but not on i-NOS. Pathol Res Pract 2006;202:1-7. (Pubitemid 43115585)
48. Nakatani K, Horinouchi J, Yabu Y, Wada H, Nobori T. Expression of endothelial nitric oxide synthase is induced by estrogen with glycogen synthase 3β phosphorylation in MCF-7 cells. Oncol Rep 2004;12:833-836
49. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology 2003;144:3449-3455 (Pubitemid 36904421)
50. Yallampalli C, Dong Y. Estradiol-17β inhibits nitric oxide synthase (NOS)-II and stimulates NOS-III gene expression in the rat uterus. Biol Reprod 2000;63:34-41. (Pubitemid 30429382)
51. Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase. Cancer Res 2003;63:6602-6606 (Pubitemid 37336434)
52. Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 2002;52:83-88 (Pubitemid 34038830)
53. Fan L, Goh BC, Wong CI, et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 2008;18:621-631
54. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365: 1687-1717
55. Venturelli E, Galimberti D, Lovati C, et al. The T-786C NOS3 polymorphism in Alzheimer's disease: association and influence on gene expression. Neurosci Lett 2005;382:300-303 (Pubitemid 40733640)
56. Song J, Yoon Y, Park KU, et al. Genotype-specific influence on nitric oxide synthase gene expression, protein concentrations, and enzyme activity in cultured human endothelial cells. Clin Chem 2003;49:847-852 (Pubitemid 36623461)
57. Tang S. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials? Cancer Invest 2008; 26:481-490
58. James RM, Reid EM, Rebbeck T, Ambrosone CB, Shields PG. Trials and interventions in molecular epidemiology. Molecular epidemiology: applications in cancer and other human diseases. Informa Healthcare; 2008, p. 29-40.
59. Ambrosone CB, Ahn J, Singh KK, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 2005;65: 1105-1111 (Pubitemid 40216474)
60. Cassileth BR, Vickers AJ. High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care. J Clin Oncol 2005;23:2590-2592 (Pubitemid 46179446)